Key result
A 10-fold increase in TTV load is linked to ~26% lower kidney allograft rejection risk.
Why the study?
The challenge of balancing immunosuppressive therapy to prevent organ rejection without promoting infection after kidney transplantation motivates investigation of Torque teno virus load as a marker of functional immunity.
Does Torque teno virus (TTV) load predict allograft rejection and viral infection in kidney transplantation recipients?
Cohort (n=389)
No
Does Torque teno virus (TTV) load predict allograft rejection and viral infection in kidney transplantation recipients?
Hazard Ratio: 0.74 (95% CI 0.71–0.76)
TTV load kinetics predict allograft rejection in kidney transplantation recipients, suggesting its potential use as a marker for functional immunity to guide immunosuppressive therapy.
TTV load was associated with lower rejection risk in kidney transplant recipients; leaves open its utility for guiding immunosuppression.
The main challenge of immunosuppressive therapy after solid organ transplantation is to create a new immunological balance that prevents organ rejection and does not promote opportunistic infection. Torque teno virus (TTV) a ubiquitous and non-pathogenic single-stranded DNA virus has been proposed as a marker of functional immunity in immunocompromised patients. Here investigate whether TTV loads predict the risk of common viral infection and allograft rejection in kidney transplantation recipients. In a retrospective cohort of 389 kidney transplantation recipients, individual TTV loads in were measured by qPCR in consecutive plasma samples during one year follow-up. The endpoints were allograft rejection, BK polyomavirus (BKPyV) viremia and cytomegalovirus (CMV) viremia. Repeated TTV measurements and rejection and infection survival data were analysed in a joint model. During follow-up, TTV DNA detection in the transplant recipients increased from 85 to 100%. The median viral load increased to 10 7 genome copies/ml within three months after transplantation. Rejection, BKPyV viremia and CMV viremia occurred in 23%, 27% and 17% of the patients, respectively. With every 10-fold TTV load-increase, the risk of rejection decreased considerably (HR: 0.74, CI 95%: 0.71-0.76), while the risk of BKPyV and CMV viremia remained the same (HR: 1.03, CI 95%: 1.03-1.04 and HR: 1.01, CI 95%: 1.01-1.01). In conclusion, TTV load kinetics predict allograft rejection in kidney transplantation recipients, but not the BKPyV and CMV infection. The potential use of TTV load levels as a guide for optimal immunosuppressive drug dosage to prevent allograft rejection deserves further validation.
No takes yet. Share an insight, caveat, or question.
Rijn et al. (2021) conducted a cohort in Kidney transplantation (n=389). Torque teno virus (TTV) load vs. Lower TTV load was evaluated on Allograft rejection (HR 0.74, 95% CI 0.71-0.76). Every 10-fold increase in Torque teno virus load significantly decreased the risk of allograft rejection (HR 0.74) in kidney transplant recipients, but did not predict BKPyV or CMV viremia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: